DENTSPLY SIRONA (XRAY) 2026 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
2026 Global Healthcare Conference summary
15 Sep, 2026Leadership and organizational transformation
Executive team strengthened with new talent and board members, including expertise in banking and dental distribution.
Lean and Agile methodologies implemented to drive customer focus and operational speed.
Resource reallocation prioritized toward customer-facing roles, with back-office streamlining to fund sales force expansion.
Integration of previously acquired businesses underway to centralize support and enhance efficiency.
Commitment to a 24-month turnaround plan, maintaining urgency and aiming for stabilization and growth.
Strategic initiatives in core business segments
Dealer network selectively expanded in the U.S. and Canada to increase equipment penetration.
Verticalization of sales force by clinical specialty and investment in clinical education to accelerate market penetration.
Focus on revitalizing CEREC and DS Core integration to drive single-visit dentistry adoption.
R&D investment to support both evolutionary and disruptive innovation, with increased spend expected next year.
Digital workflow enhancements targeted for both equipment and implant segments.
Implant and orthodontics business outlook
Expansion of value implant sales force and DSO channel underway, with investments continuing through 2027 and beyond.
Focus on high-density geographies for value implants, with Europe ahead of the U.S. in execution.
Ortho business (SureSmile) under strategic review; current focus on specialists and hybrid treatments, with potential for further investment or divestiture.
Robotic bent wires and software modernization seen as key differentiators in ortho.
Latest events from DENTSPLY SIRONA
- Q2 2026 net income rebounded, margins improved, and 2026 guidance was reaffirmed.XRAY
Q2 2026 - EPS and margins rose in Q1 2025 as cost cuts and DS Core drive recovery plans for key divisions.XRAY
Stifel Jaws & Paws Conference 2025 - All four proposals, including board elections and incentive plan amendment, were approved.XRAY
AGM 2026 - Restructuring and digital innovation drive growth, with revenue recovery targeted by late 2026.XRAY
Stifel Jaws & Paws Conference 2026 - Q1 2026 saw flat sales, a net loss, lower margins, and ongoing restructuring and innovation.XRAY
Q1 2026 - Virtual meeting to vote on directors, auditors, compensation, and incentive plan amendment.XRAY
Proxy filing - Board recommends FOR all proposals, emphasizing governance, pay-for-performance, and ESG progress.XRAY
Proxy filing - Turnaround plan drives digital innovation, operational efficiency, and growth in a $33B market.XRAY
44th Annual J.P. Morgan Healthcare Conference - FY24 net loss of $910M on lower sales; 2025 outlook sees margin and EPS growth.XRAY
Q4 2024